Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

NCT00522665 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Irinotecan
BIOLOGICAL: Cetuximab
BIOLOGICAL: RAD001

Sponsor

Hoosier Cancer Research Network

Collaborators

[object Object]
[object Object]